home All News open_in_new Full Article
Enigma Biomedical USA, Inc. Announces Candidate Selection of Novel 4R Tau PET Imaging Biomarkers
Enigma Biomedical USA, Inc. (EB USA) has selected two 4R Tau protein PET imaging biomarkers, licensed from AbbVie, to advance into Phase 1 studies for neurodegenerative disease assessment. The biomarkers aim to aid in understanding tauopathies like Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration. Phase 1 studies will evaluate safety, dosimetry, biomarker dynamics, and optimal imaging time. EB USA aims to expand availability of this imaging technology to the scientific community.
today 9 d. ago attach_file Politics
attach_file
Transport
attach_file
Society
attach_file
Other
attach_file
Other
attach_file
Events
attach_file
Other
attach_file
Culture
attach_file
Other
attach_file
Other
attach_file
Other
attach_file
Politics
attach_file
Other
attach_file
Events
attach_file
Society
attach_file
Other
attach_file
Other
attach_file
Other
ID: 3417326516